Shero, Alys, Jack and all;
Hanifen is strictly an institutional broker/dealer and consequently the members of their 'club' are the big guys. To explain; on Wall Street penny traders consort with each other, as do Nasdaq traders and Nasdaq dealers, as do member firms. And then there are the institutions that every 'club' wants to ultimately sell to. The fact that Bob Swift's brokers are out shopping the Techniclone story to their clientele bodes well for the stock's future price.
Dr. Swift formerly worked for Lilly so he knows something of the ins and outs of Big Pharma. He's a science guy, not a tout, and leaves the selling to his brokers. I know he called the LIPO disaster and he likes Immune Response for their fundamental science. I assume we will hear just how much he likes Techniclone science when the new CEO is announced. I can also affirm what Shero said this morning about his opinion of current senior TCLN management. The fact that Dr. Swift released the follow-up tells me that he also believes the transition is about to happen.
Shero is also right about all the publicity that has been directed toward monoclonal antibodies lately. Almost any serious research effort done today will uncover the existence of Techniclone and its' leading edge science. I don't know how many times over the years that representatives of Idec, Immunomedics, Immunogen, Seragen, and others have told me that TCLN was on the verge of going under so I should ignore them and climb on their bandwagons. How Darwinian of them.
The worm has turned. In all my years of digging into Techniclone, in all the back alley research, all the channels, all the deep throat info, I have never heard or felt such a bullish faith in the future. It's like a bubbling sentiment just beneath the surface. I think Bob Swift is only the first of many serious scientist/Wall Street types who will surface this year.
I'd like to find out if Wall Street overdoses to the upside as it does to the downside. What is TCLN's upside anyway? |
